Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient.
Factors such as the rising number of hematopoietic stem cell transplants is expected to fuel the market growth during the forecast period.
For instance, according to the Center for International Blood and Marrow Transplant Research Transplant Activity Report, the number of peripheral blood hematopoietic cell transplants (HCTs) performed in the U.S. were as follows:
|
DISEASE CATEGORY |
2015 |
2016 |
2017 |
|
Acute lymphoblastic leukemia (ALL) |
1,322 |
1,314 |
1,430 |
|
Acute myelogenous leukemia (AML) |
3,264 |
3,359 |
3,365 |
|
Multiple myeloma (MM) |
6,970 |
7,507 |
7,722 |
|
Total |
21,487 |
21,839 |
22,863 |
The global hematopoietic stem cell transplantation market is estimated to be valued at US$ 2,092.6 million in 2020 and is expected to exhibit a CAGR of 11.2% during the forecast period (2020-2027).
Figure 1: Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%) Analysis, By Transplant Type, 2020
-market-fig-1.png "Hematopoietic Stem Cell Transplantation | CMI")
Rising incidence of leukemia and lymphoma is driving the growth of the global hematopoietic stem cell transplantation market.
The increasing prevalence of leukemia and lymphoma is expected to drive the hematopoietic stem cell transplantation market growth during the forecast period.
As per the 2019 report by Leukemia and Lymphoma Society, an estimated 176,200 individuals in the U.S. were diagnosed with leukemia, lymphoma or myeloma and approximately 1,399,180 individuals were living with leukemia, lymphoma or myeloma. The increasing incidence rate is expected to drive demand for hematopoietic stem cell transplantation, thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market.
According to the World Cancer Research Fund 2018 report, one third of the cancer cases (globally) occur in economically developed economies such as the U.S. and Europe owing to lack of physical activity, obesity, and/or poor nutrition. Furthermore, around 90% of leukemia occurs in the middle age and develops with aging.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 2,092.6 Mn |
| Historical Data for: | 2017 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 11.2% | 2027 Value Projection: | US$ 4,391.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc. and Stempeutics Research Pvt Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Hematopoietic Stem Cell Transplantation (HSCT) Market- Restraints
Side effects of hematopoietic stem cell transplantation on organs and body parts such as gastrointestinal tract, mouth, heart, lungs which are associated with the conditioning regimen and others and serious complication of graft vs. host disease are expected to slow down the growth of the hematopoietic stem cell transplantation market.
Graft-versus-host disease (GVHD) is the complication of standard allogeneic and reduced-intensity allogeneic stem cell transplantations which occurs when the graft view the patient’s healthy cells (the host) as foreign, and attack and damage them. A close HLA match between the donor and patient helps to lower the risk of GVHD, but it does not eliminate it. Graft-versus-host disease can be mild, moderate, or severe. In some cases, it can be life-threatening.
Hematopoietic Stem Cell Transplantation (HSCT) Market– Regional Analysis
North America accounted for the largest share in the hematopoietic stem cell transplantation market owing to the increasing incidence of leukemia, lymphoma, or myeloma. For instance, according to the Leukemia and Lymphoma Society, an estimated 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017, thus leading to increasing adoption of stem cells for its efficient treatment.
Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising number of HSCT transplants in the region. For instance, according to the Japanese Data Center for Hematopoietic Cell Transplantation, the number of transplants in Japan were as follows:
-market-fig-2.png "Hematopoietic Stem Cell Transplantation | CMI")
Figure 3: Hematopoietic Stem Cell Transplantation (HSCT) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
-market-fig-3.png "Hematopoietic Stem Cell Transplantation | CMI")
Hematopoietic Stem Cell Transplantation (HSCT) Market- Competitive Landscape
Key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.
Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources; 1) autologous, that uses stem cells from the patient’s own body, 2) and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.
Market Dynamics
The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma. According to Center for Disease Control and Prevention (CDC), in the U.S., around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). According to the same source the condition is more prevalent among men than women. Leukemia accounts for around 3% of all new cancer cases.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients